A Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Study of CERC-301 in the Adjunctive Treatment of Subjects With Severe Depression and Recent Active Suicidal Ideation Despite Antidepressant Treatment

PHASE2CompletedINTERVENTIONAL
Enrollment

1,357

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

September 30, 2014

Study Completion Date

October 31, 2014

Conditions
Major Depressive Disorder
Interventions
DRUG

CERC-301

OTHER

Placebo

Trial Locations (24)

10128

The Medical Research Network, New York

10549

Bioscience Research, Mount Kisco

14618

Finger Lakes Clinical Research, Rochester

19063

Suburban Research Associates, Media

21285

Sheppard Pratt Health System, Baltimore

30060

Northwest Behavioral Research Center, Marietta

30308

Atlanta Center for Medical Research, Atlanta

32256

Clinical Neuroscience Solutions, Jacksonville

32806

Clinical Neuroscience Solutions, Orlando

33161

Scientific Clinical Research, Inc., North Miami

35294

University of Alabama at Birmingham, Birmingham

44718

Neuro-Behavioral Clinical Research, Inc., Canton

60602

Chicago Psychiatry Associates, Chicago

63368

PCRC, O'Fallon

75231

FutureSearch Trials of Dallas, Dallas

85032

Arizona TMS Therapy Center, Phoenix

90230

ProScience Research Group, Culver City

91206

Behavioral Research Specialists, Glendale

91950

Synergy Clinical Research Center, National City

92056

Southern CA Psychiatrists, Oceanside

92123

Artemis Institute for Clinical Research, San Diego

92845

Collaborative NeuroScience Network, Inc., Garden Grove

94612

Pacific Clinical Trials, LLC, Oakland

98007

Northwest Clinical Research Center, Bellevue

Sponsors
All Listed Sponsors
lead

Avalo Therapeutics, Inc.

INDUSTRY

NCT01941043 - A Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Study of CERC-301 in the Adjunctive Treatment of Subjects With Severe Depression and Recent Active Suicidal Ideation Despite Antidepressant Treatment | Biotech Hunter | Biotech Hunter